Akèy › Limfom › North Carolina › Durham
Etid klinik pou Limfom nan Durham, NC
17 etid pou Limfom ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Ap rekriteFaz 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi lwen
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- Duke University, Durham
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Ap rekriteFaz 1/2
- Duke University Medical Center, Durham
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10 mi lwen
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Ap rekrite
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi lwen
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- Duke Cancer Institute, Durham
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Ap rekrite
- North Carolina Basnight Cancer Hospital, Chapel Hill · 10 mi lwen
Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Duke University Medical Center, Duke Cancer Center, Durham
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Ap rekrite
- Duke Cancer Institute, Durham
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ap rekriteFaz 1
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi lwen
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Ap rekriteFaz 2
- Durham VA Medical Center, Durham, NC, Durham
Etid Limfom nan lòt vil
- Houston, TX34 etid
- Boston, MA33 etid
- New York City, NY33 etid
- Washington, DC23 etid
- Baldwin Park, CA21 etid
- Chicago, IL20 etid
- St. Louis, MO15 etid
- Philadelphia, PA15 etid
- Cleveland, OH14 etid
- Edison, NJ12 etid
- Atlanta, GA12 etid
- Seattle, WA12 etid
Lòt etid nan Durham
- Kansè nan tete63 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Kansè Metastatik33 etid
- Leksemi mieloïd egi33 etid
- Kansè poumon32 etid
- Kansè pwostat32 etid
- Kansè kolorektal28 etid
- Lukemi lenfositè kwonik27 etid
- Kansè ovè27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.